Etanautine, also known as diphenhydramine monoacefyllinate, is an anticholinergic used as an antiparkinsonian agent. It is a 1:1 salt of diphenhydramine with acefylline, similar to the diphenhydramine/8-chlorotheophylline combination product dimenhydrinate.[1]
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C26H31N5O5 |
Molar mass | 493.564 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
As with dimenhydrinate, the stimulant effect of the etanautine counteracts the sedative effect from the diphenhydramine, resulting in an improved therapeutic profile.[2]
The 1:2 salt diphenhydramine diacefylline (with two molecules of acefylline to each molecule of diphenhydramine) is also used in medicine, under the brand name Nautamine.[1][3]
References
edit- ^ a b Sicari V, Zabbo CP (2022). "Diphenhydramine". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30252266. Retrieved 2022-11-02.
- ^ Gonzalez F (August 21, 2009). "Diphenhydramine may be useful as a palliative treatment for patients dying with Parkinson's disease and tremors: a case report and discussion". The American Journal of Hospice & Palliative Care. 26 (6): 474–475. doi:10.1177/1049909109338937. PMID 19700649. S2CID 206633832.
- ^ "Diphenhydramine Dosage Guide + Max Dose, Adjustments". Drugs.com. Retrieved 2022-11-02.